Document is current
Any future updates will be listed below
-
Authors
Matson, Theresa E.
Navarro, Mia A.
Idu, Abisola
Bobb, Jennifer F.
Patrick, Briana M.
Phillips, Rebecca
Barrett, Tyler D.
Rossi, Fernanda S.
Krawczyk, Noa
Doud, Rachael
Rogers, Kristine
Davis, Chayna J.
Caldeiro, Ryan
Glass, Joseph E.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (P50DA054072)
- License Information
-
More Information
Article History
Received: 21 March 2025
Accepted: 28 August 2025
First Online: 1 October 2025
Declarations
:
: The KPWA Institutional Review Board granted approvals for a waiver of consent and HIPAA authorization to identify patients and conduct outcome analyses among patients eligible for inclusion in the pilot study or trial, and to identify patients for recruitment in qualitative interviews. A waiver of consent was granted to identify clinicians for participation in semi-structured interviews and focus groups. A waiver of written consent was granted to enroll patients in care navigation during the pilot study and trial and to conduct all interviews and focus groups.
: Not applicable.
: NK receives fees for expert witness testimony in ongoing opioid litigation. All other authors declare they have no competing interests.
